Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith D Eaton

Showing results (41-50 of 59) with videos related to

Pageof 6
Sort By:
BMC Cancer|January 16, 2019
Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcomePerrin E Romine, Renato G Martins, Keith D Eaton, et al.
Science Signaling|February 7, 2019
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibitionArnaud Augert, Emily Eastwood, Ali H Ibrahim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHNLaura Q M Chow, Chihiro Morishima, Keith D Eaton, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)Mark M Awad, Quincy S-C Chu, Leena Gandhi, et al.
Journal for Immunotherapy of Cancer|August 2, 2020
Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinomaSara Bedrose, Kevin Charles Miller, Lina Altameemi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2026
Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-guided and Risk-Adaptive Chemoradiation for Unresectable NSCLCJing Zeng, Sunan Cui, Daniel S Hippe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung CancerMitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Genes & Development|August 22, 2020
<i>MYCN</i> drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivityEli Grunblatt, Nan Wu, Huajia Zhang, et al.
Future Oncology (London, England)|November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib studyLyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Cancer Medicine|March 29, 2022
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patientsCameron Chalker, Jenna M Voutsinas, Qian Vicky Wu, et al.
Pageof 6

Showing results (41-50 of 59) with videos related to

Sort By:
Pageof 6
BMC Cancer|January 16, 2019
Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcomePerrin E Romine, Renato G Martins, Keith D Eaton, et al.
Science Signaling|February 7, 2019
Targeting NOTCH activation in small cell lung cancer through LSD1 inhibitionArnaud Augert, Emily Eastwood, Ali H Ibrahim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2016
Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHNLaura Q M Chow, Chihiro Morishima, Keith D Eaton, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
An open-label, phase II study of the polo-like kinase-1 (Plk-1) inhibitor, BI 2536, in patients with relapsed small cell lung cancer (SCLC)Mark M Awad, Quincy S-C Chu, Leena Gandhi, et al.
Journal for Immunotherapy of Cancer|August 2, 2020
Combined lenvatinib and pembrolizumab as salvage therapy in advanced adrenal cortical carcinomaSara Bedrose, Kevin Charles Miller, Lina Altameemi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 28, 2026
Mature Outcomes and Patterns of Failure in the Phase II FLARE-RT Trial of Biological Image-guided and Risk-Adaptive Chemoradiation for Unresectable NSCLCJing Zeng, Sunan Cui, Daniel S Hippe, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2024
Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung CancerMitchell S von Itzstein, Timothy F Burns, Jonathan E Dowell, et al.
Genes & Development|August 22, 2020
<i>MYCN</i> drives chemoresistance in small cell lung cancer while USP7 inhibition can restore chemosensitivityEli Grunblatt, Nan Wu, Huajia Zhang, et al.
Future Oncology (London, England)|November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib studyLyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Cancer Medicine|March 29, 2022
Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patientsCameron Chalker, Jenna M Voutsinas, Qian Vicky Wu, et al.
Pageof 6